US · Healthcare · Medical Devices
EPS came in at 0.59 against a street estimate of 0.56 — a beat of 5.4%.
Analysts rate Integra LifeSciences Holdings a hold (3 buy, 7 hold, 2 sell out of 12) with an average price target of $15.67.
MIXED Integra beat Q3 EPS expectations and generated strong cash, but Cincinnati disruption and tissue-reconstruction weakness cut 2026 guidance; management still expects revenue and EPS growth in 2027. Q3 FY26 International specialty surgery benefited from better availability, geographic strength, and commercial execution. Analysts focused on tissue-reconstruction recovery, Cincinnati’s duration and revenue recovery, 2027 earnings after refinancing, and capital allocation. Management emphasized execution, measured recovery, deleveraging, and productivity offsets. 2026-10-21…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.74% |
| Rubric Capital Management LP | 9.97% |
| Amvescap Plc. | 4.82% |
| Vanguard Portfolio Management, LLC | 4.81% |
| Morgan Stanley - Brokerage Accounts | 4.62% |
| Paradigm Capital Management, Inc. | 4.42% |
| Fuller & Thaler Asset Management Inc | 4.42% |
| State Street Corp | 3.79% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $411.2 million, up from $402.1 million in the third quarter of 2025. • Nine-month 2026 revenue was | 2026-10-23 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $411.2 million, up 2.3% reported and 2.5% organically versus the prior year. • GAAP diluted EPS wa | 2026-10-21 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • On October 19, 2026, Integra LifeSciences completed a debt refinancing involving a new credit agreement of up to $1.65 billion and | 2026-10-19 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Integra LifeSciences announced pricing of $450 million of 9.500% senior secured notes due 2033. • The notes were issued through a | 2026-10-09 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Integra LifeSciences expects third-quarter 2026 reported revenue of $410 million to $412 million. • Revenue includes an estimated | 2026-10-02 |
| Reg FD disclosure · Q3 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics, revenue figures, or earnings data are | 2026-09-08 |
| Quarterly report · Q2 2026 INTEGRA LIFESCIENCES HOLDINGS CORP - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $810.7 million (2026) vs. $798.3 million (202 | 2026-07-29 |
| Results announced · Q3 2026 INTEGRA LIFESCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenues: $418.8 million, up 0.8% reported / 0.7% organic vs. prior year • | 2026-07-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Integra LifeSciences Holdings — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.